| Literature DB >> 30846968 |
Mamede de Carvalho1,2, Michael Swash1,3, Susana Pinto1.
Abstract
The main reason for short survival in amyotrophic lateral sclerosis (ALS) is involvement of respiratory muscles. Severe compromise of diaphragmatic function due to marked loss of motor units causes poor inspiratory strength leading to symptomatic respiratory fatigue, and hypercapnia and hypoxemia, often firstly detected while sleeping supine. Weakness of expiratory muscles leads to cough weakness and poor bronchial clearance, increasing the risk of respiratory infection. Respiratory tests should therefore encompass inspiratory and expiratory function, and include measurements of blood gases during sleep. Non-volitional tests, such as phrenic nerve stimulation, are particularly convenient for investigating respiratory function in patients unable to perform standard respiratory function tests due to poor cooperation or facial weakness. However, SNIP is a sensitive test when patients with bulbar involvement are able to perform the necessary maneuvers. It is likely that central respiratory regulation is disturbed in some ALS patients, but its evaluation is more complex and not regularly implemented. Practical tests should incorporate tolerability, sensitivity, easy application for regular monitoring, and prognostic value. Impending respiratory failure can cause increased circulating inflammatory markers, but molecular assessment of respiratory distress requires further study. In future, home-monitoring of patients with accessible devices should be developed.Entities:
Keywords: amyotrophic lateral sclerosis; diaphragm physiology; progression; respiratory function tests; survival
Year: 2019 PMID: 30846968 PMCID: PMC6393326 DOI: 10.3389/fneur.2019.00143
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
A summary of the most relevant respiratory tests in ALS.
| ++ | ++ | ++ | + | ++ | Volitional. Limited by orofacial paresis and dyscognition. | ++ | ++ | +++ | |
| SVC | ++ | +++ | ++ | + | ++ | Volitional. Limited by orofacial paresis and dyscognition. | ++ | ++ | +++ |
| MVV | + | + | + | +? | +? | Volitional. Needs motivation; Limited by orofacial paresis, fatigue, and dyscognition. | ++ | +? | 0 |
| NPO | +++ | +++ | +++ | ++ | + | Limited by cold hands or poor sleep. | + | +++ | 0 |
| TCP | +++ | +++ | +++ | ++ | +? | Limited by cold hands and poor sleep. | ++ | +++ | 0 |
| Sleep studies | + | 0 | + | +++ | + | Limited by poor sleep. | +++ | + | 0 |
| MIP | + | + | ++ | +++ | +++ | Volitional. Limited by orofacial paresis, fatigue, and dyscognition; early floor effect. | ++ | + | 0 |
| SNIP | ++ | ++ | ++ | ++? | ++ | Volitional. Limited by orofacial paresis and dyscognition. | + | ++ | +++ |
| Diaphragm US | +++ | +++ | +++ | ++? | ++ | Limited by dyscognition. | ++ | ++ | 0 |
| Phrenic stimulation | + | ++ | ++ | + | ++ | Limited by electrical stimulation intolerance. | ++ | ++ | |
| PEF | ++ | ++ | ++ | +? | ++ | Volitional. Limited by orofacial paresis and dyscognition. | ++ | ++ | 0 |
| PCF | ++ | +++ | ++ | +? | ++ | Volitional. Limited by orofacial paresis and dyscognition. | + | ++ | 0 |
| MEP | + | + | ++ | +++ | +++ | Volitional. Limited by orofacial paresis, fatigue, and dyscognition; early floor effect. | ++ | + | 0 |
| P01 | ++ | + | + | +? | +? | Volitional. Limited by orofacial paresis, fatigue and dyscognition. | ++ | + | 0 |
FVC, forced vital capacity; SCV, slow vital capacity; MVV, maximal voluntary ventilation; NPO, nocturnal percutaneous oximetry; TCP, percutaneous capography; MIP, maximal inspiratory pressure; US, ultrasound; PEF, peak-expiratory flow; PCF, peak-cough flow; MEP, maximal expiratory pressure; P01, mouth occlusion pressure (100 ms).
*Cost (greater number of plus symbol means higher cost) was estimated taking into account equipament price and the requirement of a technician.
**Ease for monitoring was estimated considering patient confort and technical complexity.
Figure 1Represents the progressive parallel decline of FVC and phrenic nerve compound muscle action potential amplitude in an ALS patient with slow progression. Values were normalized to 100% of normal at first assessment. This figure is simply for representative purposes and not intended to present research findings.